23,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
payback
12 °P sammeln
  • Broschiertes Buch

Our study is the first to utilize the OpenVigil 2.1, a universal novel web-based pharmacovigilance analysis tool to analyze real-life safety and effectiveness of six ADHD medications with special emphasis on psychiatric adverse events. We accounted for the following ADHD medications; atomoxetine, lisdexamphetamine, amphetamine, methylphenidate (instant release, intermediate acting, long acting). We believe that thorough knowledge of adverse events for each medication helps to support treatment guidelines and clinical management of the events.

Produktbeschreibung
Our study is the first to utilize the OpenVigil 2.1, a universal novel web-based pharmacovigilance analysis tool to analyze real-life safety and effectiveness of six ADHD medications with special emphasis on psychiatric adverse events. We accounted for the following ADHD medications; atomoxetine, lisdexamphetamine, amphetamine, methylphenidate (instant release, intermediate acting, long acting). We believe that thorough knowledge of adverse events for each medication helps to support treatment guidelines and clinical management of the events.
Autorenporträt
Dottorato in Farmacia Clinica (Pharm.D.) Università Ebraica, Istituto di Ricerca sui Farmaci, Dipartimento di Farmacia Clinica, Gerusalemme. Farmacista clinico e docente di farmacoterapia specializzato in medicina interna e psicofarmacologia clinica.